上市后藥物經濟學評價方法Ⅱ：藥物經濟學原始研究_《中國循證醫學雜志》

作者：

孫鑫 ¹ , Ewa Orlewska ² , 李幼平 ¹ , 程剛 ³ , 楊煥 ⁴

1. 四川大學華西醫院循證醫學與臨床流行病學研究中心（成都 610041）2. 波蘭華沙藥物經濟學中心3. 國家食品與藥品監督管理局藥物再評價中心（北京 100061）4. 國家食品藥品監督管理總局新藥評審中心（北京 100061）;

關鍵詞：

經濟學評價上市后藥物方法

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

當現有經濟學證據的系統評價不能充分評價上市后藥物的經濟學情況時，需要開展原始的經濟學評價研究。本文主要介紹了原始經濟學評價中研究設計，成本和結果的測量，及敏感性分析的原則。總體而言，四種設計方案可用于經濟學評價，不同方案各有其優缺點。結果和成本的測量方法有多種，主要根據研究要求和適用性選擇不同的方法。對各種可能影響結果的因素應采用不同的分析方法進行分析。

引用本文： 孫鑫,Ewa Orlewska,李幼平,程剛,楊煥. 上市后藥物經濟學評價方法Ⅱ：藥物經濟學原始研究. 中國循證醫學雜志, 2006, 06(3): 218-223. doi: 復制

1.	SUN X, Orlewska E, LI YP, et al. An introduction to methods for economic evaluation of marketed medicines I: setting up an economic framework and reviewing existing evidence. Chinese Journal of Evidence-Based Medicine, 2005; 5(12): 944-949.
2.	Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol, 2003; 3: 28.
3.	MacPherson H. Pragmatic clinical trials. Complementary Therapies in Medicine, 2004; 12: 136-140.
4.	Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programs. 2nd ed. Oxford: Oxford University Press; 1997.
5.	Sonnenberg FA. Decision analysis in disease management. Disease Management and Clinica Outcomes, 1997; 1(1): 20-34.
6.	Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ, 1997; 6(3): 217-227.
7.	Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics, 2000; 17(2): 151-165.
8.	Polsky D, Willke RJ, Scott K, et al. A comparison of scoring weights for the EuroQol derived from patients and the general public. Health Econ, 2001; 10(1): 27-37.
9.	Neymark N, Kiebert W, Torfs K, et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer, 1998; 34(9): 1317-1333.
10.	Bayoumi AM. The Measurement of Contingent Valuation for Health Economics. Pharmacoeconomics, 2004; 22(11): 691-700.
11.	Levels of Evidence-March 2002. Available from: http://www.eboncall.org/content/levels.html.
12.	Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics, 2005; 23(2): 105-111.
13.	Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics, 2002; 20(7): 443-454.
14.	Nuijten MJ. Measuring sensitivity in pharmacoeconomic studies. Refining point sensitivity and range sensitivity by incorporating probability distributions. Pharmacoeconomics, 1999; 16(1): 33-41.
15.	Tambour M, Zethraeus N. Bootstrap confidence intervals for cost-effectiveness ratios: some simulation results. Health Econ, 1998; 7(2): 143-147.
16.	Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics, 2000; 17(5): 479-500.
17.	Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess, 1999; 3(2): 1-134.

1. SUN X, Orlewska E, LI YP, et al. An introduction to methods for economic evaluation of marketed medicines I: setting up an economic framework and reviewing existing evidence. Chinese Journal of Evidence-Based Medicine, 2005; 5(12): 944-949.
2. Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol, 2003; 3: 28.
3. MacPherson H. Pragmatic clinical trials. Complementary Therapies in Medicine, 2004; 12: 136-140.
4. Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programs. 2nd ed. Oxford: Oxford University Press; 1997.
5. Sonnenberg FA. Decision analysis in disease management. Disease Management and Clinica Outcomes, 1997; 1(1): 20-34.
6. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ, 1997; 6(3): 217-227.
7. Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics, 2000; 17(2): 151-165.
8. Polsky D, Willke RJ, Scott K, et al. A comparison of scoring weights for the EuroQol derived from patients and the general public. Health Econ, 2001; 10(1): 27-37.
9. Neymark N, Kiebert W, Torfs K, et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer, 1998; 34(9): 1317-1333.
10. Bayoumi AM. The Measurement of Contingent Valuation for Health Economics. Pharmacoeconomics, 2004; 22(11): 691-700.
11. Levels of Evidence-March 2002. Available from: http://www.eboncall.org/content/levels.html.
12. Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics, 2005; 23(2): 105-111.
13. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics, 2002; 20(7): 443-454.
14. Nuijten MJ. Measuring sensitivity in pharmacoeconomic studies. Refining point sensitivity and range sensitivity by incorporating probability distributions. Pharmacoeconomics, 1999; 16(1): 33-41.
15. Tambour M, Zethraeus N. Bootstrap confidence intervals for cost-effectiveness ratios: some simulation results. Health Econ, 1998; 7(2): 143-147.
16. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics, 2000; 17(5): 479-500.
17. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess, 1999; 3(2): 1-134.

《中國循證醫學雜志》

上市后藥物經濟學評價方法Ⅱ：藥物經濟學原始研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國循證醫學雜志》

上市后藥物經濟學評價方法Ⅱ：藥物經濟學原始研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料